Latest

latest

Corona: Corona epidemic breaks all sales records, 600 percent increase in sales

The drug controller allowed emergency use of the drug last year during the escalation of corona infections. In September last year, the drug was...

Tuesday, May 11, 2021

/ by Avishek Bera


 The News Cover: The drug controller allowed emergency use of the drug last year during the escalation of corona infections. In September last year, the drug was sold for 60 crore rupees across the country. But in April this year, the drug broke all sales records. Sales of that drug called Fabiflu have increased by 600 percent. Many people have relied on this drug during this difficult time of the Corona epidemic. Vaccine famine in the country. If he is infected with coronavirus, the doctors have not yet found the prescribed method of treatment. As a result, the doctors are treating the patient on the basis of the symptoms and the physical condition of the victim. In such a situation, Fabiflu has been widely used across the country.

At this time of the Corona epidemic, people are more inclined towards antiviral drugs. As a result, the use of all antiviral drugs has increased more or less. However, the use of fabiflu has increased at a massive rate. Glenmark's drug, the multivitamin drug Ginkobit, also lags far behind in terms of sales. According to the company, sales of Fabiflu have increased by almost 600 percent. Fabiflu is now the best-selling drug in the Indian pharma market. Until October last year, Ginkobit was the best-selling drug in the Indian market.

Sales of drugs such as Monosafe, Dolo, and Betadine have also increased significantly during this time. However, none of them reached the record of selling Fabiflu. The generic version of the Japanese anti-influenza drug Fabipirabir is Fabiflu. Demand for this specialty has grown significantly as a result of recent corporate scandals. The second wave of corona has hit the country. In such a situation, many are relying on this drug. According to pharma research firm AIOCD, Fabiflu has turned over a business worth 762 crore in the last one year. It is followed by the anti-diabetic drug Glycomet-GP. This drug has raised a business of 564 crore. Surprisingly, Fabiflu's total sales halved in April alone.

No comments

Post a Comment

WE WISH FOR A POLLUTION FREE INDIA
News Cover © all rights reserved
made with by templateszoo